Table 1 -. Studies included in the systematic review, conducted in the 1965-2012 period.
| Author | Study design | Age group (years) | Sample (n) | Study population | Study period | Study setting | Treatment regimen | Statistical analysis |
|---|---|---|---|---|---|---|---|---|
| Ai et al.(14) | Case-control study | ≤ 60 and > 60 | 639 | Outpatients | June of 2006 to March of 2007 | China | RHZE for 2 months + RH for 4 months | Unspecified univariate and multivariate analyses |
| Baghaei et al.(15) | Population-based cohort study | < 65 and ≥ 65 | 761 | Inpatients | January of 2006 to January of 2008 | Iran | RHZE for 6 months | Χ2, Fisher’s exact test, Mann-Whitney test, and logistic regression |
| Barnes et al.(16) | Cohort study | ≥ 15 | 161 | Inpatients | June of 1984 to March of 1985 | USA | No data | Χ2 and Fisher’s exact test |
| Cantalice Filho et al.(17) | Case-control study | 15-49 and ≥ 60 | 581 | Inpatients | January of 1980 to December of 1996 | Brazil | RHZ for 2 months + RH for 4 months | Χ2 and Fisher’s exact test |
| Cho et al.(18) | Cohort study | 51.2 ± 17.5 46.7 ± 18.4 | 132 | Inpatients | June of 2004 to December of 2005 | South Korea | RHZE for 2 months + HRE for 4 months | Mann-Whitney test, Χ2, and Fisher’s exact test |
| HKCS/BMRC(19) | Clinical trial | ≥ 15 | 620 | Unspecified | October of 1984 to October of 1986 | China | SHRZ (3×/week for 6 months) | Relative frequency (%) and absolute frequency (n), unspecified univariate analysis |
| Kelly et al.(20) | Cohort study | Mean, 34.9 and 41.7 | 187 | Inpatients | November of 1991 to May of 1993 | Africa | SHRZ for 2 months/TH for 6 months | Kaplan-Meier method, unspecified univariate and multivariate analyses |
| Khalili et al.(11) | Case-control study | 18-86 | 100 | Inpatients | September of 2006 to March of 2009 | Iran | RHZE for 2 months + RH for 4 months | Χ2 |
| Lee et al.(21) | Retrospective cohort study | 18-84 | 148 (Latent TB) | Outpatients/inpatients | April of 1999 to March of 2001 | USA | RZ for 2 months | Relative frequency (%) and absolute frequency (n), relative risk, and multivariate analysis |
| Nanashima et al.(12) | Randomized cross-sectional study | 22-94 | 100 | Inpatients | May of 2005 to September of 2006 | Japan | H (400 mg/day) + R (450 mg/day) | Mann-Whitney test, Χ2, Fisher’s exact test, and logistic regression |
| Martínez Sanchís et al.(22) | Cohort study | ≥ 10 to ≥ 64 | 198 (Latent TB) | Inpatients | December of 1996 to December of 2002 | Spain | H 300 mg/day (2 or 6 months) | Χ2, Fisher’s exact test, and logistic regression |
| Sharma et al.(23) | Cohort study | 16-80 | 346 | Inpatients | 1996-2000 | India | RHZE | Χ2 and logistic regression |
| Sirinak et al.(24) | Cohort study | ≥ 18 | 769 | Inpatients | May of 2005 to September of 2006 | Thailand | RHZE | Unspecified univariate analysis and logistic regression |
| Teixeira et al.(25) | Case-control study | > 18 | 167 | Inpatients | 1998-2008 | Brazil | H (400 mg/day) + others | Mann-Whitney test, Χ2, Fisher’s exact test, Student’s t-test, etc. |
| Teleman et al.(26) | Retrospective cohort study | 16-82 | 783 | Outpatients | January of 1998 to December of 1998 | Singapore | RHZ for 9 months + E or S | Mann-Whitney test, Χ2, Fisher’s exact test, and logistic regression |
| No authors listed(13) | Clinical trial | ≥ 12 | 908 | Outpatients | Unspecified | India | R3/R5/Z5 | Relative frequency (%) and absolute frequency (n), unspecified univariate analysis |
TB: tuberculosis; HKCS: Hong Kong Chest Service; BMRC: British Medical Research Council; R: rifampin; H: isoniazid; Z: pyrazinamide; E: ethambutol; S: streptomycin; T: thiocetazone; R3: rifampin-streptomycin-isoniazid-pyrazinamide daily for 3 months; R5: rifampin-streptomycin-isoniazid-pyrazinamide daily for 3 months, followed by streptomycinisoniazid- pyrazinamide twice a week for 2 months; Z5: streptomycin-isoniazid-pyrazinamide daily for 3 months, followed by streptomycin-isoniazid-pyrazinamide twice a week for 2 months; and Χ2: chi-square test.